Anti-hypertensive effect of Siddha formulation Imbural Vadagam against Human angiotensin converting enzyme using In-Silico model
Keywords:Siddha Medicine, Imbural vadagam, Hypertension, Angiotensin converting enzyme inhibitor, Docking study, ACE
Background: Siddha Medicine is emerging as the treatment of choice for various diseases. Hypertension is one among the comorbidities which plays a major role leading to stroke, cardiovascular diseases and renal failure. Objective: To perform the In Silico computational studies of phytocomponents of Imbural vadagam and to evaluate its anti-hypertensive potential. Methods: Auto dock program was used for the molecular docking studies against Angiotensin Converting Enzyme(ACE). Results: Asperulosidic acid, 6α-Hydroxygeniposide, Piperic acid, Piperine, Apigenin, Orientin and Vitexin that exist in the siddha drug Imbural vadagam exhibit remarkable binding against the target Angiotensin converting enzyme. Conclusion: It can be that these phytocomponents exhibit remarkable antihypertensive activity.
How to Cite
Copyright (c) 2023 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.